As a healthcare provider, we understand you are interested in reviewing clinical data when determining how to best treat your patients.

Below you’ll find recent clinical information for both of our products. If you have specific questions or would like to request additional information, please use the form at the bottom of the page.




Clinical References

NoctoPlex 

Benson, Kathleen F PhD and Gitte S Jensen PhD. Evaluation of Novel Nutraceutical Sleep Aid on Sleep Quality and Additional Parameters. Lab Study. Union Springs,LLC. Klamath Falls, OR: NIS Labs, 2013. Print. April 2013.

Parrott, A. C. and I. Hindmarch. “The Leeds Sleep Evaluation Questionnaire in Psychopharmacological Investigations – a Review.” Psychopharmacology 71 (1980):173-179. Print. July 2014.

Rosenthal, Martha S. “Physiology and Neurochemistry of Sleep.” American Journal of Pharmaceutical Education 62 (1998): 204-208. Print. July 2014.

Weeks, Benjamin S. “Formulations of dietary supplements and herbal extracts forrelaxation and anxiolytic action: Relarian™.” Medical Science Monitor 15 (2009):RA256-262. Print. July 2014.

LuciPlex

Amaducci, L. “Phosphatidylserine in the Treatment of Alzhiemer’s Disease: Resultsfrom a Multicenter Study.” Psychopharmacology Bulletin 24.1 (1988): 130-134.Print.

Argentiero, V. and B. Tavolato. “Dopamine (DA) and Serotonin Metabolic Levels inthe Cerebrospinal Fluid (CSF) in Alzheimer’s Presenile Dementia Under BasicConditions and After Stimulation with Cerebral Cortex Phospholipids (BC-PL).”Journal of Neurology 224 (1980): 53-58. Web. 20 May 2014.

Cenacchi, T., et al. “Cognitive Decline in the Elderly: a Double-Blind, Placebo-Controlled Multicenter Study on Efficacy of Phosphatidylserine Administration.”Aging Clinical and Experimental Research 5.2 (1993): 123-133. Web. 20 May 2014.

Crook, T.H., PhD, et al. “Effects of Phosphatidylserine in Age-Associated MemoryImpairment.” Neurology 41 (1991): 644-649. Print. July 2014.

Crook, Thomas, PhD, et al. “Effects of Phosphatidylserine in Alzheimer’s Disease.”Psychopharmacology Bulletin 28.1 (1992): 61-66. Print. July 2014.

Heiss, W.D., et al. “Long-Term Effects of Phosphatidylserine, Pyritinol, and CognitiveTraining in Alzheimer’s Disease.” Dementia and Geriatric Cognitive Disorders 5.2(1994): 88-98. Web. 31 July 2014.

Kato-Kataoka, Akito, et al. “Soybean-Derived Phosphatidylserine Improves MemoryFunction of the Elderly Japanese Subjects with Memory Complaints.” Journal ofClinical Biochemistry and Nutrition 47 (2010): 246-255. Print. July 2014.

Louis-Sylvestre, J. “Phosphatidylserine et Troubles Mnesiques Du Sujet Age.” Cahiersde Nutrition et de Dietetique 34.6 (1999): 349-357. Print. 22 July 2014.

Soderberg, M., et al. “Fatty Acid Composition of Brain Phospholipids in Aging and inAlzheimer’s Disease.” Lipids 26.6 (1991): 421-425. Web. 20 May 2014.

Vakhapova, Veronika, et al. “Phosphatidylserine Containing ω-3 Fatty Acids May Improve Memory Abilities in Non-Demented Elderly with Memory Complaints: ADouble-Blind Placebo-Controlled Trial.” Dementia and Geriatric Cognitive Disorders29 (2010): 467-474. Web. July 2014.

Young, Genevieve and Julie Conquer. “Omega-3 Fatty Acids and Neuropsychiatric Disorders.” Reproduction Nutrition Development 45 (2005): 1-28. Web. July 2014.

Antony, B., et al. “A Pilot Cross-Over Study to Evalutae Human Oral Bioavailability ofBCM-95®CG (Biocurcumax™), A Novel Bioenhanced Preparation of Curcumin.”Indian Journal of Pharmaceutical Sciences 70.4 (2008): 445-449. Web. July 2014.

Baum, Larry, PhD, et al. “Six-Month Randomized, Placebo-Controlled, Double-Blind,Pilot Clinical Trial of Curcumin in Patients with Alzheimer Disease.” Journal ofClinical Psychopharmacology 28.1 (2008): 110-113. Print. July 2014.
Benny, Dr. Merina and Dr. Benny Antony. “Bioavailability of Biocurcumax™ (BCM-095™).” Spice Board India 19.9 (2006): 11-15. Print. July 2014.

Chin, Dawn, et al. “Neuroprotective Properties of Curcumin – Merits andLimitations.” Current Medicinal Chemistry 20.32 (2013): 3955-3985. Web. July 2014.

Sanmukhani, Jayesh, Ashish Anovadiya and Chandrabhanu B. Tripathi. “Evaluationof Antidepressant Like Activity of Curcumin and Its Combination with Fluoxetine and Imipramine: an Acute and Chronic Study.” Acta Poloniae Pharmaceutica – DrugResearch 68.5 (2011): 769-775. Print. July 2014.

Sanmukhani, Jayesh, et al. “Efficacy and Safety of Curcumin in Major DepressiveDisorder: A Randomized Controlled Trial.” Phytotherapy Research (2013). Web. July 2014.

Akbaraly, N. Tasnime, et al. “Plasma Selenium Over Time and Cognitive Decline inthe Elderly: Results of the EVA Study.” Epidemiology 18.1 (2007): 52-58. Print. July2014.

Cheng, Y., et al. “Abstract of [Study on Selenium Exposure Level Related to CognitiveFunction in Rural Elderly People].” Wei Sheng Yan Jiu = Journal of Hygiene Research39.4 (2010): 483-485. Web. July 2014 [Full Journal in Chinese].

Daniells, Stephen. Lifelong Selenium Intake May Slow Age-Related Cognitive Decline.Commentary on “Selenium Level and Cognitive Function in Rural Elderly Chinese”.William Reed Business Media. 13 February 2007. Web. July 2014.—.

Selenium Supplements Could Slow Age-Related Cognitive Decline. Commentaryon “Plasma Selenium Over Time and Cognitive Decline in the Elderly. William Reed Business Media. 2 February 2007. Web. July 2014.

Gao, Sujuan, et al. “Selenium Level and Cognitive Function in Rural Elderly Chinese.”American Journal of Epidemiology 165 (2007): 955-965. Web. July 2014.—. “Selenium Level is Associated with apoE E4 in Rural Elderly Chinese.” Public Health Nutrition 12.12 (2009): 2371-2376. Web. July 2014.

Ishrat, Tauheed, et al. “Selenium Prevents Cognitive Decline and Oxidative Damagein Rat Model of Streptozotocin-Induced Experimental Dementia of Alzheimer’sType.” Brain Research 1281.24 (2009): 117-127. Web. 20 May 2014.

Annweiler, Cédric, et al. “Higher Vitamin D Dietary Intake is Associated with LowerRisk of Alzheimer’s Disease: a 7-Year Follow-up.” J Gerontol A Biol Sci Med Sci 67.11(2012): 1205-1211. Web. July 2014.

de Jager, Celeste A., et al. “Cognitive and Clinical Outcomes of Homocysteine-Lowering B-Vitamin Tratment in Mild Cognitive Impairment: a RandomizedControlled Trial.” International Journal of Geriatric Psychiatry 27.6 (2012): 592-600.Web. July 2014.

Douaud, Gwenaëlle, et al. “Preventing Alzheimer’s Disease-Related Gray MatterAtrophy by B-Vitamin Treatment.” Proceedings of the National Academy of Sciences 110.23 (2013): 9523-9528. Web. July 2014.